CN106421650B - A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation - Google Patents

A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation Download PDF

Info

Publication number
CN106421650B
CN106421650B CN201610956867.3A CN201610956867A CN106421650B CN 106421650 B CN106421650 B CN 106421650B CN 201610956867 A CN201610956867 A CN 201610956867A CN 106421650 B CN106421650 B CN 106421650B
Authority
CN
China
Prior art keywords
chinese medicine
preparation
medicine composition
ocular fundus
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610956867.3A
Other languages
Chinese (zh)
Other versions
CN106421650A (en
Inventor
李卉
石丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEILIN PHARMACEUTICAL Co Ltd XI'AN
Original Assignee
BEILIN PHARMACEUTICAL Co Ltd XI'AN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEILIN PHARMACEUTICAL Co Ltd XI'AN filed Critical BEILIN PHARMACEUTICAL Co Ltd XI'AN
Priority to CN201610956867.3A priority Critical patent/CN106421650B/en
Publication of CN106421650A publication Critical patent/CN106421650A/en
Application granted granted Critical
Publication of CN106421650B publication Critical patent/CN106421650B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a kind of Chinese medicine compositions to treat the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation, belongs to pharmaceutical technology field.Applicant to and the clinical research and zoopery of XUEMINGMU PIAN in, it was found that it has good therapeutic effect for senile ocular fundus arteriosclerosis clinically, in materia medica research process, applicant, which adds and subtracts taste principle by Chinese medicine, joined paniculate swallowwort on the basis of the prescription with XUEMINGMU PIAN, find it to the therapeutic effect of senile ocular fundus arteriosclerosis more preferably after schizonepeta and Rhizoma Atractylodis Macrocephalae, the Chinese medicine composition, which can significantly improve, reduces TC, the indexs such as TG and significantly raising HDL, more estimable is that its antiphlogistic effects and Atorvastatin have significant difference, therefore there is good potential applicability in clinical practice.

Description

A kind of Chinese medicine composition treats senile ocular fundus arteriosclerosis and fundus flavimaculatus in preparation Purposes in lesion drug
Technical field
The present invention relates to a kind of and blood improving eyesight Chinese medicine composition new applications, and in particular to prepared by the Chinese medicine composition The purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug is treated, pharmaceutical technology field is belonged to.
Background technique
Senile ocular fundus arteriosclerosis is the common eyeground pathological changes of 50~60 years old or more the elderly, with advancing age, Disease incidence gradually rises.Advanced age leads to artery whole body system degeneration, diffusivity hardening, and fiber-like occurs in ductus arteriosus wall middle layer And vitreous degeneration, small number of patients are also possible to related with inherent cause.Senile ocular fundus arteriosclerosis is systemic arteriosclerosis One typical case's " signal ", the people with senile ocular fundus arteriosclerosis, systemic arterial blood vessel have hardening more.
Senile ocular fundus arteriosclerosis is a kind of chronic senile Blood vessel pattern, is a kind of aging phenomenon of human body.It is old Property arteriosclerotic retinopathy, is the performance of the non-inflammation degeneration and proliferative lesion of artery on the retina.With Artery wall thickening changes elasticity and is hardened as main feature.The elderly for generally betiding 50~60 years old is to invade systemic arterial The degeneration and diffusivity artery sclerosis of system.The weight of eyeground pathological changes degree and the urgency of development are slow, the degree with whole body pathology It is related with progress.Eyeground pathological changes caused by these systemic diseases develop to a certain extent, will damage to visual function, need Positive remedy measures are taken in time.
Although senile ocular fundus arteriosclerosis can be such that mental and physical exertion weakens, serious tissue is seldom caused to damage Wound, eye can without any symptom, but check when can be found that Fundus oculi artery generally attenuate, color it is thin out with it is reflective dimmed.Have When due to choroidal arteriosclerosis can make retina generate it is secondary sexually revise, such as pigment disorder, glass-film wart, or even cause old Property macular degeneration.Patient usually pays attention to taking in high heat, high-fat, high cholesterol class food less as far as possible in diet；Eat vegetable more Dish, fruit；Smoking cessation limit wine, not overeating；Pleasant mood is kept, is done more physical exercises.It is generally acknowledged that these methods are in certain journey It can delay the process of old ocular fundus arteriosclerosis on degree.If can accelerate old with hypertension, hyperlipidemia and diabetes etc. simultaneously The process of year property ocular fundus arteriosclerosis, and senile ocular fundus arteriosclerosis can also aggravate the Eye disease of above-mentioned disease in turn, So the patient for suffering from hypertension, hyperlipidemia and diabetes wants active treatment, in order to avoid cause serious Eye disease and blind.
Currently, clinically the drug for treating senile ocular fundus arteriosclerosis mainly has (1) lipid regulating agent: mainly logical Reduction TC and LDL is crossed to alleviate the state of an illness, represents drug as Statins and bile acid binding resin class；(2) antioxidant: main It is confrontation oxygen free radicals in blood and ox-LDL to achieve the purpose that the senile ocular fundus arteriosclerosis for the treatment of, representing drug has general sieve Cloth examines (probucol) and vitamin E；(3) polyenoic fatty acids (PUFA): it is divided into N-6 type polyenoic fatty acid and N-3 type polyenoid On the one hand fatty acid, such drug are by adjusting blood lipid, be on the other hand to expand blood vessel by inhibiting platelet aggregation, change Kind microcirculation achievees the purpose that treatment；(4) mucopolysaccharide and polysaccharide: such drug can protect vascular endothelial cell, prevent blood The transfer of pipe smooth muscle cell and proliferation, representing drug has low molecular weight heparin and Heparan sulfate.Said medicine is old in treatment Be essentially all in terms of year property ocular fundus arteriosclerosis by lipid-loweringing, the anti-oxidant degree to mitigate senile ocular fundus arteriosclerosis, The development process of patch can not fundamentally be prevented it is therefore seen that, the drug of the senile ocular fundus arteriosclerosis of clinical treatment is still not Can be satisfactory, it researches and develops a kind of senile ocular fundus arteriosclerosis therapeutic agent and still has important practical significance and economic valence Value.
Differentiation of tcm improves patient body function on the whole, accumulates in terms for the treatment of senile ocular fundus arteriosclerosis Experience and theory abundant, have reached preferable effect.It is the Chinese materia medica preparation produced by Forest of Steles in Xi'an medicine company with XUEMINGMU PIAN, Clinic cures mainly cooling blood and hemostasis, enriching yin stagnation resolvation, nourishes the liver to improve visual acuity.For deficiency of Yin liver-yang hyperactivity, fundus hemorrhage caused by thermal burn channels.Country " the national standard for traditional Chinese medicines compilation ophthalmology ear-nose-throat department dermatology fascicle " promulgated food and medicine Surveillance Authority in December, 2002 " and XUEMINGMU PIAN " under WS-10062 (ZD-0062) -2002 discloses its prescription and preparation method.
On October 29th, 2003, Chinese patent publication disclosed " a kind of Chinese medicine for treating optical fundus hemorrhage and its preparation side Method ", the patent application of Publication No. CN1451422A, composition invent the weight proportion of each herbal medicine raw material of the Chinese patent drug Are as follows: 65-80 parts of cattail pollen, 65-80 parts of Radix Salviae Miltiorrhizae, 50-70 parts of glutinous rehmannia, 50-70 parts of eclipta, 40-60 parts of chrysanthemum, charcoal radix scutellariae 35-50 Part, 35-50 parts of cassia seed, 35-50 parts of semen plantaginis, 35-50 parts of Semen Leonuri, 35-50 parts of the fruit of glossy privet, 35-50 parts of Prunella vulgaris, rough gentian 35-50 parts, 20-40 parts of Radix Curcumae, 35-50 parts of scouring rush, 20-40 parts of radix paeoniae rubra, 20-40 parts of cortex moutan, 20-40 parts of hawthorn, Radix Angelicae Sinensis 20- 40 parts, 5-15 parts of Rhizoma Chuanxiong.
Chinese invention patent CN102319398B discloses a kind of and XUEMINGMU PIAN improvement prescription, composition are as follows: Cattail pollen 75g, Radix Salviae Miltiorrhizae 75g, glutinous rehmannia 60g, eclipta 40g, chrysanthemum 50g, charcoal radix scutellariae 45g, cassia seed 45g, semen plantaginis 45g, motherwort Sub- 45g, fruit of glossy privet 45g, Prunella vulgaris 45g, rough gentian 45g, Radix Curcumae 15g, scouring rush 30g, radix paeoniae rubra 30g, cortex moutan 30g, hawthorn 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g, increase Rhizoma Chuanxiong dosage simultaneously reduce the dosage of eclipta, Radix Curcumae and scouring rush after, discovery for Deficiency of Yin liver-yang hyperactivity, the enhancing significant in efficacy of fundus hemorrhage caused by thermal burn channels, and it is without any side effects.
Chinese invention patent CN102319400B discloses a kind of and XUEMINGMU PIAN new preparation process, original and On the basis of XUEMINGMU PIAN technique, discovery mentions the water in its technique be changed to the extractions of 6 times of 60% ethyl alcohol of amount after, effective component mentions Rate is taken to significantly improve, clinical pharrnacokinetics experiment effect significantly improves, and stability is good, and safe without toxic side effect.
Summary of the invention
Applicant to and the clinical research and zoopery of XUEMINGMU PIAN in, find it for senile eye clinically Bottom artery sclerosis has good therapeutic effect, and which results in the concerns of applicant, in materia medica research process, applicant By Chinese medicine add and subtract taste principle to and the prescription of XUEMINGMU PIAN have made intensive studies, develop one kind and be specially adapted for old eye The Chinese medicine composition of bottom artery sclerosis and fundus flavimaculatus lesions treatment, based on this, the present invention is specifically proposed.
The above-mentioned technical effect of the present invention is achieved through the following technical solutions:
A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation, The wherein composition of the Chinese medicine composition are as follows: cattail pollen 75g, Radix Salviae Miltiorrhizae 75g, glutinous rehmannia 60g, eclipta 40g, chrysanthemum 50g, charcoal Radix scutellariae 45g, cassia seed 45g, semen plantaginis 45g, Semen Leonuri 45g, fruit of glossy privet 45g, Prunella vulgaris 45g, rough gentian 45g, Radix Curcumae 15g, wood Crafty 30g, radix paeoniae rubra 30g, cortex moutan 30g, hawthorn 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g.
On the basis of above-mentioned prescription, after paniculate swallowwort, schizonepeta and Rhizoma Atractylodis Macrocephalae is added, senile ocular fundus arteriosclerosis is controlled Therapeutic effect significantly increases, and therapeutic effect obviously has exceeded the expection of those skilled in the art.Applicant according to after prescription to old age The enhancing of the therapeutic effect of property ocular fundus arteriosclerosis has carried out further preferably prescription, it is preferable that the Chinese medicine composition Also contain paniculate swallowwort 30g, schizonepeta 25g and Rhizoma Atractylodis Macrocephalae 20g.Or preferably, the Chinese medicine composition also contain paniculate swallowwort 15g, Schizonepeta 15g and Rhizoma Atractylodis Macrocephalae 20g.
In medicinal usage described above, the pharmaceutical preparation comprising Chinese medicine composition is its oral preparation, described Oral preparation is its tablet, capsule, granule, syrup, one of pill, preferably its tablet.The Chinese traditional medicine composition The preparation method of the pharmaceutical preparation of object can be prepared according to preparation process well-known to those skilled in the art.Preferably, The preparation method of the pharmaceutical preparation of the Chinese medicine composition includes the following steps:
Accurate to claim recipe quantity Chinese medicine, chrysanthemum, charcoal radix scutellariae, half amount semen plantaginis, partly amount cattail pollen, co-grinding are standby at fine powder With；Remaining semen plantaginis, cattail pollen and remaining each taste add 60% ethyl alcohol to impregnate 30 minutes, and refluxing extraction is secondary, and 2 hours every time, first Secondary plus 6 times of 60% ethyl alcohol amounts, second plus 6 times of 60% ethyl alcohol amounts, merge extracting solution twice, filtration；Time control is concentrated in filtrate decompression Vacuum degree processed is -0.08MPa, temperature is 80 DEG C, is concentrated into the thick paste that relative density is 1.35~1.39 when temperature is 60 DEG C, adds Enter above-mentioned fine powder to be uniformly mixed, 60 DEG C of drying are ground into fine powder, each dosage form proper auxiliary materials are added, by each dosage form common process system At tablet, capsule, granule or pill.
The embodiment of the present invention 9 find, Serum bichemisbry the result shows that, compared with Normal group, model group HDL significantly drops Low, other indexs significantly increase, and have statistical difference, show modeling success；Compared with model group, traditional Chinese medicine composition for treating group It is significantly increased with Atorvastatin group HDL, all other indexs significantly reduce, index no significant difference between two groups, show The effect for reducing fat of drug composition is suitable with Atorvastatin；Compared with model group, traditional Chinese medicine composition for treating group MM-9 and VCAM-1 It significantly reduces, there is statistical difference (P < 0.05), also show with the difference of conspicuousness compared with Atorvastatin group Drug composition treatment group is better than Atorvastatin in antiphlogistic effects.
It is of the present invention to use on the way, if the senile ocular fundus arteriosclerosis patient is simultaneously with fundus flavimaculatus disease Become, the traditional chinese medicine composition of the invention can also be substantially reduced fundus flavimaculatus lesion degree, therefore for senile ocular fundus arteriosclerosis There is positive therapeutic effect with the patient of fundus flavimaculatus lesion simultaneously.
The traditional chinese medicine composition of the invention has the beneficial effect that compared with prior art
1) and XUEMINGMU PIAN is clinically using the Chinese materia medica preparation of the various fundus hemorrhages for the treatment of of many years, and applicant is in reality Test it is middle discovery its have the effect for the treatment of senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion well, and it is found by the applicant that its For senile ocular fundus arteriosclerosis therapeutic effect with and XUEMINGMU PIAN in prescription Chinese medicine dosage relation it is very big, Chinese medicine The dosage of material changes, and the therapeutic effect of senile ocular fundus arteriosclerosis is remarkably decreased.
2) it is hard for senile Fundus oculi artery after paniculate swallowwort, schizonepeta and Rhizoma Atractylodis Macrocephalae being added on the basis of with XUEMINGMU PIAN prescription The therapeutic effect of change significantly increases, this shows that three kinds of Chinese medicines being added and original prescription produce the senile Fundus oculi artery for the treatment of The synergy for hardening aspect, preferably finds by prescription, when addition paniculate swallowwort 30g, schizonepeta 25g and Rhizoma Atractylodis Macrocephalae 20g, or Xu are long When minister in ancient times 15g, schizonepeta 15g and Rhizoma Atractylodis Macrocephalae 20g, therapeutic effect is the most excellent.
3) it is clinically applied for many years with XUEMINGMU PIAN, there is good clinical practice experience, drug safety, user Just, it brings glad tidings to countless patients, present invention discover that the treatment new application with XUEMINGMU PIAN, can greatly extend and blood improving eyesight The clinical use range of piece, and drug safety is high.
Specific embodiment
The present invention is further described below by way of specific embodiment, but the embodiment does not limit this hair in any way Bright scope of patent protection.
1 present invention of embodiment is for treating the Chinese medicine composition of senile ocular fundus arteriosclerosis
A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation, The wherein composition of the Chinese medicine composition are as follows: cattail pollen 75g, Radix Salviae Miltiorrhizae 75g, glutinous rehmannia 60g, eclipta 40g, chrysanthemum 50g, charcoal Radix scutellariae 45g, cassia seed 45g, semen plantaginis 45g, Semen Leonuri 45g, fruit of glossy privet 45g, Prunella vulgaris 45g, rough gentian 45g, Radix Curcumae 15g, wood Crafty 30g, radix paeoniae rubra 30g, cortex moutan 30g, hawthorn 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g.
Preparation process: accurate to claim recipe quantity Chinese medicine, chrysanthemum, charcoal radix scutellariae, half amount semen plantaginis, half amount cattail pollen, co-grinding It is spare at fine powder；Remaining semen plantaginis, cattail pollen and remaining each taste add 60% ethyl alcohol to impregnate 30 minutes, and refluxing extraction is secondary, and every time 2 Hour, for the first time plus 6 times of 60% ethyl alcohol amounts, second plus 6 times of 60% ethyl alcohol amounts merge extracting solution twice, filtration；Filtrate decompression Control vacuum degree is -0.08MPa when concentration, temperature is 80 DEG C, and being concentrated into relative density when temperature is 60 DEG C is 1.35~1.39 Thick paste, be added above-mentioned fine powder be uniformly mixed, 60 DEG C drying, be ground into fine powder, each dosage form proper auxiliary materials be added, it is normal by each dosage form Tablet, capsule, granule or pill is made in rule technique.
2 present invention of embodiment is for treating the Chinese medicine composition of senile ocular fundus arteriosclerosis
A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation, The wherein composition of the Chinese medicine composition are as follows: cattail pollen 75g, Radix Salviae Miltiorrhizae 75g, glutinous rehmannia 60g, eclipta 40g, chrysanthemum 50g, charcoal Radix scutellariae 45g, cassia seed 45g, semen plantaginis 45g, Semen Leonuri 45g, fruit of glossy privet 45g, Prunella vulgaris 45g, rough gentian 45g, Radix Curcumae 15g, wood Crafty 30g, radix paeoniae rubra 30g, cortex moutan 30g, hawthorn 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g, paniculate swallowwort 30g, schizonepeta 25g and Rhizoma Atractylodis Macrocephalae 20g.
Preparation process is the same as embodiment 1.
3 present invention of embodiment is for treating the Chinese medicine composition of senile ocular fundus arteriosclerosis
The pharmaceutical preparation of Chinese medicine composition is prepared according to following prescription ratio respectively, wherein removing paniculate swallowwort, schizonepeta and Rhizoma Atractylodis Macrocephalae Dosage have outside difference, remaining prescription ratio is the same as embodiment 2.
Paniculate swallowwort in 1 embodiment 3-6 pharmaceutical preparation of table, schizonepeta and Rhizoma Atractylodis Macrocephalae dosage
Prescription Paniculate swallowwort (g) Schizonepeta (g) Rhizoma Atractylodis Macrocephalae (g)
Embodiment 3 15 15 20
Embodiment 4 30 20 20
Embodiment 5 45 25 20
Embodiment 6 30 20 30
Embodiment 7 45 25 30
Embodiment 8 15 20 30
Therapeutic effect of 9 the traditional chinese medicine composition of the invention of embodiment to senile ocular fundus arteriosclerosis new zealand rabbit
1. experimental method
80 healthy new zealand white rabbits are taken, weight is 2.5~3.0kg, is randomly divided into Normal group, model comparison Totally 10 groups of group, Chinese medicine composition low, middle and high dose groups, Atorvastatin group, every group 8, all male, all animals are remembered Number pen traces Arabic numerals in left ear to distinguish individual.The leading stomach-filling of animal newborn 1 month high in fat, the detection of ear edge arterial blood extracting was dynamic After object TG, TC are increased, yellow Jackets 30mg/kg auricular vein injecting anesthetic rejects neck coat, and disinfection, surgical exposure are dynamic Object left common carotid 2.5cm or so, is successively pressed from both sides with artery clamp and closes blood vessel proximal part and distal end, and artery-sparing is long between both ends Degree is 2cm or so, draws 1% concentration sodium laurate 0.1ml with insulin injection syringe and injects blood vessel, unclamps distal end blood after 5min Pipe clamp unclamps again proximal part after cotton balls hemostasis by compression, sews up a wound, rearging cage is put back to after disinfection treatment.Postoperative muscle for three days on end Inject 800,000 units of Penicillin disinfection after, start gastric infusion, administration the time limit be 2 months, be administered once daily, at the same daily after Continuous stomach-filling cream high in fat.
5. experimental result
Ear edge arterial blood extracting 4ml, centrifuging and taking serum detect detection blood using automatic clinical chemistry analyzer after two months for administration Clear TG (blood lipid), TC (cholesterol), HDL (high-density lipoprotein), LDL (low-density lipoprotein), are detected using enzyme-linked immunization MM-9 (Matrix Metalloproteinase-9), VCAM-1 (vascular cell adhesion melecule)；Animal sacrificed by exsanguination takes left side neck always to move Arteries and veins does immunohistochemistry, detects the senile ocular fundus arteriosclerosis degree of arteria carotis communis.
Therapeutic effect of the different treatment groups of table 2 to senile ocular fundus arteriosclerosis new zealand rabbit
Compared with Normal group,##P<0.01；*Compared with 1 group of Chinese medicine,*P < 0.05, compared with Atorvastatin group,▼p <0.05。
As can be seen from Table 2, Serum bichemisbry the result shows that, compared with Normal group, model group HDL significantly reduce, it is other Index significantly increases, and has statistical difference, shows modeling success；Compared with model group, traditional Chinese medicine composition for treating group and atropic It cuts down statin group HDL significantly to increase, all other indexs significantly reduce, and index no significant difference between two groups shows Chinese traditional medicine composition The effect for reducing fat of object is suitable with Atorvastatin；Compared with model group, traditional Chinese medicine composition for treating group MM-9 and VCAM-1 is significant It reduces, there is statistical difference (P < 0.05), also show Chinese traditional medicine composition with the difference of conspicuousness compared with Atorvastatin group Object treatment group is better than Atorvastatin (being shown in Table 2) in antiphlogistic effects.
Concrete outcome is as follows:
1) TG, TC, LDL of 1 group for the treatment of group of Chinese medicine are significantly reduced compared with model group, and HDL is significant compared with model group to be risen Height has significant difference, this shows that 1 group of Chinese medicine (i.e. with the prescription of XUEMINGMU PIAN) can be used as senile ocular fundus arteriosclerosis Therapeutic agent uses.
2) 2 group of -8 group TG, TC, LDL of Chinese medicine are significantly reduced compared with 1 group of Chinese medicine, and HDL is significant compared with 1 group of Chinese medicine to be increased, With significant difference, this shows treating senile eye after being added into paniculate swallowwort, schizonepeta and Rhizoma Atractylodis Macrocephalae on the basis of 1 group of Chinese medicine Significant synergistic effect is achieved between original prescription drug in terms of the artery sclerosis of bottom, wherein especially with 2 groups of Chinese medicine and Chinese medicine 3 Group is best, for optimal two embodiments of the present invention.
3) 2 group of -8 group of Chinese medicine is compared with Atorvastatin group in MM-9 content and VCAM-1 content and Atorvastatin group Compared to significant decrease, this shows that paniculate swallowwort, schizonepeta and Rhizoma Atractylodis Macrocephalae are added in prescription makes the antiphlogistic effects of Chinese medicine composition significant Enhancing, can be effectively prevented patch for senile ocular fundus arteriosclerosis and falls off, so that the drug safety of patient increases.
Meanwhile model group animal blood vessels endothelium defect, proliferation of fibrous tissue are subendothelial visible as the result is shown for Histopathology Angiogenesis, the visible endothelial injuries of Atorvastatin group are subendothelial to have foam cells, visible a large amount of vacuoles in endochylema, smooth muscle Hyperplasia, each treatment group of Chinese medicine composition have no angiogenesis and proliferation of smooth muscle, and rarely seen subendothelial have the foam cells being dispersed in, table The inhibitory effect that bright Chinese medicine composition develops senile ocular fundus arteriosclerosis is better than Atorvastatin.
In summary, it is believed that Chinese medicine composition is mitigating senile ocular fundus arteriosclerosis inflammatory reaction, inhibiting patch Development aspect is better than Atorvastatin, can effectively treat senile ocular fundus arteriosclerosis.

Claims (6)

1. a kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis drug in preparation, wherein the Chinese medicine group Close the composition of object are as follows: cattail pollen 75g, Radix Salviae Miltiorrhizae 75g, glutinous rehmannia 60g, eclipta 40g, chrysanthemum 50g, charcoal radix scutellariae 45g, cassia seed 45g, semen plantaginis 45g, Semen Leonuri 45g, fruit of glossy privet 45g, Prunella vulgaris 45g, rough gentian 45g, Radix Curcumae 15g, scouring rush 30g, radix paeoniae rubra 30g, Cortex moutan 30g, hawthorn 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g, paniculate swallowwort 30g, schizonepeta 25g and Rhizoma Atractylodis Macrocephalae 20g.
2. a kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis drug in preparation, wherein the Chinese medicine group Close the composition of object are as follows: cattail pollen 75g, Radix Salviae Miltiorrhizae 75g, glutinous rehmannia 60g, eclipta 40g, chrysanthemum 50g, charcoal radix scutellariae 45g, cassia seed 45g, semen plantaginis 45g, Semen Leonuri 45g, fruit of glossy privet 45g, Prunella vulgaris 45g, rough gentian 45g, Radix Curcumae 15g, scouring rush 30g, radix paeoniae rubra 30g, Cortex moutan 30g, hawthorn 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g, paniculate swallowwort 15g, schizonepeta 15g and Rhizoma Atractylodis Macrocephalae 20g.
3. purposes according to claim 1 to 2, which is characterized in that the pharmaceutical preparation comprising Chinese medicine composition is Its oral preparation.
4. purposes according to claim 3, which is characterized in that the oral preparation is its tablet, capsule, particle Agent, syrup, one of pill.
5. purposes according to claim 1 or 2, which is characterized in that the preparation side of the pharmaceutical preparation of the Chinese medicine composition Method includes the following steps:
Accurate to claim recipe quantity Chinese medicine, chrysanthemum, charcoal radix scutellariae, half amount semen plantaginis, partly amount cattail pollen, co-grinding are spare at fine powder；It is surplus Remaining semen plantaginis, cattail pollen and remaining each taste add 60% ethyl alcohol to impregnate 30 minutes, and refluxing extraction is secondary, 2 hours every time, add for the first time 60% 6 times of ethyl alcohol amount, second plus 6 times of 60% ethyl alcohol amounts, merges extracting solution twice, filtration；Control is true when filtrate decompression is concentrated Reciprocal of duty cycle is -0.08MPa, temperature is 80 DEG C, is concentrated into the thick paste that relative density is 1.35~1.39 when temperature is 60 DEG C, in addition It states fine powder to be uniformly mixed, 60 DEG C of drying are ground into fine powder, each dosage form proper auxiliary materials are added, piece is made by each dosage form common process Agent, capsule, granule or pill.
6. purposes according to claim 1 or 2, which is characterized in that the senile ocular fundus arteriosclerosis patient is simultaneously With fundus flavimaculatus lesion.
CN201610956867.3A 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation Active CN106421650B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610956867.3A CN106421650B (en) 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610956867.3A CN106421650B (en) 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation

Publications (2)

Publication Number Publication Date
CN106421650A CN106421650A (en) 2017-02-22
CN106421650B true CN106421650B (en) 2019-08-13

Family

ID=58180190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610956867.3A Active CN106421650B (en) 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation

Country Status (1)

Country Link
CN (1) CN106421650B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255344A (en) * 1998-11-30 2000-06-07 万前烈 Typhlosis-resistant liquid for ophthalmopathy as complication of diabetes
CN1283477A (en) * 2000-07-13 2001-02-14 郭连川 'Yanming' capsules for clearing eyes
CN102319400A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 Traditional Chinese drug composition for blood cooling, hemostasis, yin nourishing, blood stasis dissipating, liver nourishing and eyesight improving, and preparation method thereof
CN102319398A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 A kind of and the blood Chinese medicine composition and preparation method thereof that makes eye bright

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255344A (en) * 1998-11-30 2000-06-07 万前烈 Typhlosis-resistant liquid for ophthalmopathy as complication of diabetes
CN1283477A (en) * 2000-07-13 2001-02-14 郭连川 'Yanming' capsules for clearing eyes
CN102319400A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 Traditional Chinese drug composition for blood cooling, hemostasis, yin nourishing, blood stasis dissipating, liver nourishing and eyesight improving, and preparation method thereof
CN102319398A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 A kind of and the blood Chinese medicine composition and preparation method thereof that makes eye bright

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
糖尿病性视网膜病变动脉硬化程度与中药治疗介入时机的相关性研究;吕小利等;《浙江中西医结合杂志》;20100115;第20卷(第01期);第9-11页

Also Published As

Publication number Publication date
CN106421650A (en) 2017-02-22

Similar Documents

Publication Publication Date Title
CN102048894A (en) Traditional Chinese medicine composition for treating burn and preparation method thereof
CN104206594A (en) Herba Taxilli health-care tea capable of lowering blood pressure and blood lipid and preparation method thereof
CN103749824B (en) A kind of Herb Gynostemmae Pentaphylli blood sugar lowering blood pressure depressing health tea and preparation method thereof
CN101342356B (en) Traditional Chinese medicine preparation for congestion retardarce, haemal tube obstruction and preparation method thereof
CN102846824B (en) Traditional Chinese medicinal composition for treating cold dampness blood stasis blocking channel type diabetic feet, and its preparation method
CN103550688B (en) A kind of Chinese medicine composition for the treatment of cardiopalmus
CN103585449B (en) For treating migrainous Chinese medicine composition
CN105012873A (en) Health-care blood-fat-lowering evening primrose oral liquid and preparation method thereof
CN106421650B (en) A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation
CN105056103A (en) Steamed buns with assistant effect of reducing blood fat and cholesterol and processing method of steamed buns
CN104147186B (en) Flos rosae multiflorae quintessence oil hydrogel plaster and preparation method thereof
CN103638336B (en) Full rhizoma gastrodiae tablet
CN103656226A (en) Compound medicine for treating sicca syndrome
CN102824506B (en) Traditional Chinese medicine preparation for treating aplastic anemia
CN105106758A (en) Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness
CN101884735B (en) Medicament for treating dyslipidemia and preparation method thereof
CN109010700A (en) A kind of Chinese medicine composition that treating diabetes, preparation and its application
CN108743885A (en) A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications
CN1248684C (en) Chinese medicine powder for curing cardiovascular disease and preparing method thereof
CN111643557B (en) Pharmaceutical composition for preventing and treating sequela of deep venous thrombosis of lower limbs and preparation method and application thereof
CN1050759C (en) Medicinal composite for hysteromyoma and preparing method
CN105833094A (en) Traditional Chinese medicine composition for treating trachoma
CN106266334A (en) A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application
CN105832934A (en) Traditional Chinese medicine for treating hypertension
CN105030993A (en) Chinese medicine compound, toxin expelling liquid and preparation method of toxin expelling liquid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant